{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T20:38:28Z","timestamp":1784061508205,"version":"3.55.0"},"reference-count":98,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplantation Reviews"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1016\/j.trre.2024.100857","type":"journal-article","created":{"date-parts":[[2024,4,30]],"date-time":"2024-04-30T16:37:59Z","timestamp":1714495079000},"page":"100857","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Recurrent complement-mediated Hemolytic uremic syndrome after kidney transplantation"],"prefix":"10.1016","volume":"38","author":[{"given":"Shota","family":"Obata","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Hullekes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonardo V.","family":"Riella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Cravedi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.trre.2024.100857_bb0005","doi-asserted-by":"crossref","first-page":"554","DOI":"10.2215\/CJN.04760512","article-title":"Genetics and outcome of atypical hemolytic uremic syndrome: a Nationwide French series comparing children and adults","volume":"8","author":"Fremeaux-Bacchi","year":"2013","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.trre.2024.100857_bb0010","doi-asserted-by":"crossref","first-page":"e33","DOI":"10.1053\/j.ajkd.2016.10.006","article-title":"AJKD atlas of renal pathology: thrombotic microangiopathy","volume":"68","author":"Lusco","year":"2016","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.trre.2024.100857_bb0015","doi-asserted-by":"crossref","first-page":"2847","DOI":"10.1182\/blood-2016-11-709865","article-title":"HUS and atypical HUS","volume":"129","author":"Jokiranta","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.trre.2024.100857_bb0020","doi-asserted-by":"crossref","first-page":"1722","DOI":"10.1016\/S0140-6736(22)01202-8","article-title":"Haemolytic uraemic syndrome","volume":"400","author":"Michael","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.trre.2024.100857_bb0025","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1016\/j.kint.2023.07.020","article-title":"On the relevance of thrombomodulin variants in atypical hemolytic uremic syndrome","volume":"104","author":"Huerta","year":"2023","journal-title":"Kidney Int"},{"key":"10.1016\/j.trre.2024.100857_bb0030","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1038\/s41581-021-00424-4","article-title":"Thrombotic microangiopathy in aHUS and beyond: clinical clues from complement genetics","volume":"17","author":"Fakhouri","year":"2021","journal-title":"Nat Rev Nephrol"},{"key":"10.1016\/j.trre.2024.100857_bb0035","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/j.kint.2016.10.005","article-title":"Atypical hemolytic uremic syndrome and C3 glomerulopathy: conclusions from a \u201cKidney Disease: Improving Global Outcomes\u201d (KDIGO) controversies conference","volume":"91","author":"Goodship","year":"2017","journal-title":"Kidney Int"},{"key":"10.1016\/j.trre.2024.100857_bb0040","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1016\/j.kint.2019.01.023","article-title":"Atypical and secondary hemolytic uremic syndromes have a distinct presentation and no common genetic risk factors","volume":"95","author":"Le Clech","year":"2019","journal-title":"Kidney Int"},{"key":"10.1016\/j.trre.2024.100857_bb0045","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1016\/j.kint.2018.02.029","article-title":"Clinical and genetic predictors of atypical hemolytic uremic syndrome phenotype and outcome","volume":"94","author":"Schaefer","year":"2018","journal-title":"Kidney Int"},{"key":"10.1016\/j.trre.2024.100857_bb0050","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/nrdp.2017.20","article-title":"Thrombotic thrombocytopenic purpura","volume":"3","author":"Kremer Hovinga","year":"2017","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.trre.2024.100857_bb0055","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1056\/NEJMra020528","article-title":"Thrombotic Microangiopathies","volume":"347","author":"Moake","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.trre.2024.100857_bb0060","doi-asserted-by":"crossref","first-page":"648","DOI":"10.3390\/jcm11030648","article-title":"Urine protein\/creatinine ratio in thrombotic microangiopathies: a simple test to facilitate thrombotic thrombocytopenic purpura and hemolytic and uremic syndrome diagnosis","volume":"11","author":"Burguet","year":"2022","journal-title":"J Clin Med"},{"key":"10.1016\/j.trre.2024.100857_bb0065","doi-asserted-by":"crossref","first-page":"e157","DOI":"10.1016\/S2352-3026(17)30026-1","article-title":"Derivation and external validation of the PLASMIC score for rapid assessment of adults with thrombotic microangiopathies: a cohort study","volume":"4","author":"Bendapudi","year":"2017","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.trre.2024.100857_bb0070","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1111\/jth.13882","article-title":"External validation of the PLASMIC score: a clinical prediction tool for thrombotic thrombocytopenic purpura diagnosis and treatment","volume":"16","author":"Li","year":"2018","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.trre.2024.100857_bb0075","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1016\/j.kint.2019.05.014","article-title":"Severe and malignant hypertension are common in primary atypical hemolytic uremic syndrome","volume":"96","author":"Cavero","year":"2019","journal-title":"Kidney Int"},{"key":"10.1016\/j.trre.2024.100857_bb0080","doi-asserted-by":"crossref","first-page":"2501","DOI":"10.3324\/haematol.2019.216903","article-title":"Impact of hypertensive emergency and rare complement variants on the presentation and outcome of atypical hemolytic uremic syndrome","volume":"104","author":"El Karoui","year":"2019","journal-title":"Haematologica"},{"key":"10.1016\/j.trre.2024.100857_bb0085","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1097\/HJH.0000000000001913","article-title":"Malignant hypertension: diagnosis, treatment and prognosis with experience from the Bordeaux cohort","volume":"37","author":"Rubin","year":"2019","journal-title":"J Hypertens"},{"key":"10.1016\/j.trre.2024.100857_bb0090","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1182\/blood.2020005221","article-title":"Management of thrombotic microangiopathy in pregnancy and postpartum: report from an international working group","volume":"136","author":"Fakhouri","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.trre.2024.100857_bb0095","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1182\/blood-2014-02-558296","article-title":"Dynamics of complement activation in aHUS and how to monitor eculizumab therapy","volume":"124","author":"Noris","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.trre.2024.100857_bb0100","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.trre.2017.10.001","article-title":"De novo thrombotic microangiopathy after kidney transplantation","volume":"32","author":"Garg","year":"2018","journal-title":"Transplant Rev"},{"key":"10.1016\/j.trre.2024.100857_bb0105","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.trre.2018.01.001","article-title":"Innate networking: thrombotic microangiopathy, the activation of coagulation and complement in the sensitized kidney transplant recipient","volume":"32","author":"Manook","year":"2018","journal-title":"Transplant Rev (Orlando)"},{"key":"10.1016\/j.trre.2024.100857_bb0110","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2015.00262","article-title":"Complement system part I \u2013 molecular mechanisms of activation and regulation","volume":"6","author":"Merle","year":"2015","journal-title":"Front Immunol"},{"key":"10.1016\/j.trre.2024.100857_bb0115","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1107\/S0907444909000389","article-title":"The structure of C2b, a fragment of complement component C2 produced during C3 convertase formation","volume":"65","author":"Krishnan","year":"2009","journal-title":"Acta Crystallogr D Biol Crystallogr"},{"key":"10.1016\/j.trre.2024.100857_bb0120","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1111\/j.1365-3083.2005.01685.x","article-title":"M-ficolin, an innate immune defence molecule, binds patterns of acetyl groups and activates complement","volume":"62","author":"Frederiksen","year":"2005","journal-title":"Scand J Immunol"},{"key":"10.1016\/j.trre.2024.100857_bb0125","doi-asserted-by":"crossref","first-page":"47513","DOI":"10.1074\/jbc.M407161200","article-title":"L-ficolin is a pattern recognition molecule specific for acetyl groups","volume":"279","author":"Krarup","year":"2004","journal-title":"J Biol Chem"},{"key":"10.1016\/j.trre.2024.100857_bb0130","first-page":"109","article-title":"The influence of C3b inactivator (KAF) concentration on the ability of serum to support complement activation","volume":"21","author":"Lachmann","year":"1975","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.trre.2024.100857_bb0135","doi-asserted-by":"crossref","first-page":"4458","DOI":"10.1021\/bi00518a034","article-title":"Nucleophilic modification of human complement protein C3: correlation of conformational changes with acquisition of C3b-like functional properties","volume":"20","author":"Isenman","year":"1981","journal-title":"Biochemistry"},{"key":"10.1016\/j.trre.2024.100857_bb0140","doi-asserted-by":"crossref","first-page":"7540","DOI":"10.1096\/fj.201902397R","article-title":"In response to complement anaphylatoxin peptides C3a and C5a, human vascular endothelial cells migrate and mediate the activation of B-cells and polarization of T-cells","volume":"34","author":"Shivshankar","year":"2020","journal-title":"FASEB J"},{"key":"10.1016\/j.trre.2024.100857_bb0145","series-title":"Immunobiology: The immune system in health and disease","article-title":"The complement system and innate immunity","author":"Charles","year":"2001"},{"key":"10.1016\/j.trre.2024.100857_bb0150","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1084\/jem.142.4.856","article-title":"Properdin: binding to C3b and stabilization of the C3b-dependent C3 convertase","volume":"142","year":"1975","journal-title":"J Exp Med"},{"key":"10.1016\/j.trre.2024.100857_bb0155","doi-asserted-by":"crossref","first-page":"1908","DOI":"10.1021\/bi500157z","article-title":"The making of a macromolecular machine: assembly of the membrane attack complex","volume":"53","author":"Bubeck","year":"2014","journal-title":"Biochemistry"},{"key":"10.1016\/j.trre.2024.100857_bb0160","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1007\/s10238-018-0491-8","article-title":"The role of the alternative pathway of complement activation in glomerular diseases","volume":"18","author":"\u0141ukawska","year":"2018","journal-title":"Clin Exp Med"},{"key":"10.1016\/j.trre.2024.100857_bb0165","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1007\/s00239-004-2609-8","article-title":"Amino acid patterns within short consensus repeats define conserved duplicons shared by genes of the RCA complex","volume":"59","author":"McLure","year":"2004","journal-title":"J Mol Evol"},{"key":"10.1016\/j.trre.2024.100857_bb0170","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1038\/ni.1755","article-title":"Structure of C3b-factor H and implications for host protection by complement regulators","volume":"10","author":"Wu","year":"2009","journal-title":"Nat Immunol"},{"key":"10.1016\/j.trre.2024.100857_bb0175","doi-asserted-by":"crossref","first-page":"352","DOI":"10.4049\/jimmunol.178.1.352","article-title":"Decay-accelerating factor must bind both components of the complement alternative pathway C3 convertase to mediate efficient decay","volume":"178","author":"Harris","year":"2007","journal-title":"J Immunol"},{"key":"10.1016\/j.trre.2024.100857_bb0180","doi-asserted-by":"crossref","first-page":"3478","DOI":"10.4049\/jimmunol.144.9.3478","article-title":"The complement-inhibitory activity of CD59 resides in its capacity to block incorporation of C9 into membrane C5b-9","volume":"144","author":"Rollins","year":"1990","journal-title":"J Immunol"},{"key":"10.1016\/j.trre.2024.100857_bb0185","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1002\/ajmg.c.31986","article-title":"C3 glomerulopathy: understanding an ultra-rare complement-mediated renal disease","volume":"190","author":"Heiderscheit","year":"2022","journal-title":"Am J Med Genet C Semin Med Genet"},{"key":"10.1016\/j.trre.2024.100857_bb0190","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.660194","article-title":"A family affair: addressing the challenges of factor H and the related proteins","volume":"12","author":"Poppelaars","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.trre.2024.100857_bb0195","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1016\/S0140-6736(03)14742-3","article-title":"Familial haemolytic uraemic syndrome and an MCP mutation","volume":"362","author":"Noris","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.trre.2024.100857_bb0200","doi-asserted-by":"crossref","first-page":"15650","DOI":"10.1074\/jbc.M900814200","article-title":"Mutations of factor H impair regulation of surface-bound C3b by three mechanisms in atypical hemolytic uremic syndrome","volume":"284","author":"Lehtinen","year":"2009","journal-title":"J Biol Chem"},{"key":"10.1016\/j.trre.2024.100857_bb0205","doi-asserted-by":"crossref","first-page":"2150","DOI":"10.1681\/ASN.2005010103","article-title":"Mutations in complement factor I predispose to development of atypical hemolytic uremic syndrome","volume":"16","author":"Kavanagh","year":"2005","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.trre.2024.100857_bb0210","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1073\/pnas.0603420103","article-title":"Gain-of-function mutations in complement factor B are associated with atypical hemolytic uremic syndrome","volume":"104","author":"de Jorge","year":"2007","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.trre.2024.100857_bb0215","doi-asserted-by":"crossref","first-page":"4948","DOI":"10.1182\/blood-2008-01-133702","article-title":"Mutations in complement C3 predispose to development of atypical hemolytic uremic syndrome","volume":"112","author":"Fr\u00e9meaux-Bacchi","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.trre.2024.100857_bb0220","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.931210","article-title":"Anti-factor H antibody and its role in atypical hemolytic uremic syndrome","volume":"13","author":"Raina","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.trre.2024.100857_bb0225","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1056\/NEJMoa0810739","article-title":"Thrombomodulin mutations in atypical hemolytic\u2013uremic syndrome","volume":"361","author":"Delvaeye","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.trre.2024.100857_bb0230","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1038\/ng.2622","article-title":"DGKE and atypical HUS","volume":"45","author":"Quaggin","year":"2013","journal-title":"Nat Genet"},{"key":"10.1016\/j.trre.2024.100857_bb0235","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1182\/blood.2020006931","article-title":"Familial risk of developing atypical hemolytic-uremic syndrome","volume":"136","author":"Arjona","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.trre.2024.100857_bb0240","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1681\/ASN.2012090884","article-title":"Combined complement gene mutations in atypical hemolytic uremic syndrome influence clinical phenotype","volume":"24","author":"Bresin","year":"2013","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.trre.2024.100857_bb0245","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/j.semnephrol.2013.08.003","article-title":"Atypical hemolytic uremic syndrome","volume":"33","author":"Kavanagh","year":"2013","journal-title":"Semin Nephrol"},{"key":"10.1016\/j.trre.2024.100857_bb0250","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.trre.2013.04.002","article-title":"Eculizumab in renal transplantation","volume":"27","author":"Legendre","year":"2013","journal-title":"Transplant Rev"},{"key":"10.1016\/j.trre.2024.100857_bb0255","doi-asserted-by":"crossref","first-page":"2185","DOI":"10.1182\/blood.2021012037","article-title":"Functional characterization of 105 factor H variants associated with aHUS: lessons for variant classification","volume":"138","author":"Mart\u00edn Merinero","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.trre.2024.100857_bb0260","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.trre.2013.07.003","article-title":"Targeted strategies in the prevention and management of atypical HUS recurrence after kidney transplantation","volume":"27","author":"Zuber","year":"2013","journal-title":"Transplant Rev"},{"key":"10.1016\/j.trre.2024.100857_bb0265","doi-asserted-by":"crossref","first-page":"88","DOI":"10.2215\/CJN.00050505","article-title":"Outcome of renal transplantation in patients with non\u2013Shiga toxin\u2013associated hemolytic uremic syndrome: prognostic significance of genetic background","volume":"1","author":"Bresin","year":"2006","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.trre.2024.100857_bb0270","first-page":"422","article-title":"Genetics of atypical hemolytic uremic syndrome (aHUS)","author":"C\u00f3rdoba","year":"2014","journal-title":"Semin Thromb Hemost"},{"key":"10.1016\/j.trre.2024.100857_bb0275","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1038\/nrneph.2010.155","article-title":"New insights into postrenal transplant hemolytic uremic syndrome","volume":"7","author":"Zuber","year":"2011","journal-title":"Nat Rev Nephrol"},{"key":"10.1016\/j.trre.2024.100857_bb0280","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1111\/j.1600-6143.2008.02297.x","article-title":"Complement mutation-associated de novo thrombotic microangiopathy following kidney transplantation","volume":"8","author":"Le Quintrec","year":"2008","journal-title":"Am J Transplant"},{"key":"10.1016\/j.trre.2024.100857_bb0285","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1016\/j.ekir.2023.01.016","article-title":"Eculizumab rescue therapy in patients with recurrent atypical hemolytic uremic syndrome after kidney transplantation","volume":"8","author":"Duineveld","year":"2023","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.trre.2024.100857_bb0290","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1111\/ajt.12077","article-title":"Complement genes strongly predict recurrence and graft outcome in adult renal transplant recipients with atypical hemolytic and uremic syndrome","volume":"13","author":"Le Quintrec","year":"2013","journal-title":"Am J Transplant"},{"key":"10.1016\/j.trre.2024.100857_bb0295","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1053\/j.ajkd.2015.12.034","article-title":"Terminal complement inhibitor eculizumab in adult patients with atypical hemolytic uremic syndrome: a single-arm, open-label trial","volume":"68","author":"Fakhouri","year":"2016","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.trre.2024.100857_bb0300","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1016\/j.kint.2015.11.026","article-title":"Eculizumab is a safe and effective treatment in pediatric patients with atypical hemolytic uremic syndrome","volume":"89","author":"Greenbaum","year":"2016","journal-title":"Kidney Int"},{"key":"10.1016\/j.trre.2024.100857_bb0305","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1056\/NEJMoa1208981","article-title":"Terminal complement inhibitor eculizumab in atypical hemolytic\u2013uremic syndrome","volume":"368","author":"Legendre","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.trre.2024.100857_bb0310","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/S0140-6736(17)30062-4","article-title":"Haemolytic uraemic syndrome","volume":"390","author":"Fakhouri","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.trre.2024.100857_bb0315","doi-asserted-by":"crossref","first-page":"50","DOI":"10.2215\/CJN.06440616","article-title":"Pathogenic variants in complement genes and risk of atypical hemolytic uremic syndrome relapse after eculizumab discontinuation","volume":"12","author":"Fakhouri","year":"2017","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.trre.2024.100857_bb0320","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1093\/ndt\/gfx196","article-title":"Safety and effectiveness of restrictive eculizumab treatment in atypical haemolytic uremic syndrome","volume":"33","author":"Wijnsma","year":"2018","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.trre.2024.100857_bb0325","doi-asserted-by":"crossref","first-page":"2438","DOI":"10.1182\/blood.2020009280","article-title":"Eculizumab discontinuation in children and adults with atypical hemolytic-uremic syndrome: a prospective multicenter study","volume":"137","author":"Fakhouri","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.trre.2024.100857_bb0330","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1093\/ckj\/sfab005","article-title":"Eculizumab discontinuation in atypical haemolytic uraemic syndrome: TMA recurrence risk and renal outcomes","volume":"14","author":"Ariceta","year":"2021","journal-title":"Clin Kidney J"},{"key":"10.1016\/j.trre.2024.100857_bb0335","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.ekir.2022.10.013","article-title":"Early Eculizumab withdrawal in patients with atypical hemolytic uremic syndrome in native kidneys is safe and cost-effective: results of the CUREiHUS study","volume":"8","author":"Bouwmeester","year":"2023","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.trre.2024.100857_bb0340","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1182\/bloodadvances.2021006416","article-title":"Complement gene variant effect on relapse of complement-mediated thrombotic microangiopathy after eculizumab cessation","volume":"7","author":"Acosta-Medina","year":"2022","journal-title":"Blood Adv"},{"key":"10.1016\/j.trre.2024.100857_bb0345","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1182\/bloodadvances.2020003175","article-title":"Outcomes of a clinician-directed protocol for discontinuation of complement inhibition therapy in atypical hemolytic uremic syndrome","volume":"5","author":"Chaturvedi","year":"2021","journal-title":"Blood Adv"},{"key":"10.1016\/j.trre.2024.100857_bb0350","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1007\/s40620-021-01212-w","article-title":"Eculizumab treatment and discontinuation in pediatric patients with atypical hemolytic uremic syndrome: a multicentric retrospective study","volume":"35","author":"Baskin","year":"2022","journal-title":"J Nephrol"},{"key":"10.1016\/j.trre.2024.100857_bb0355","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1053\/j.ajkd.2014.01.434","article-title":"Discontinuation of eculizumab maintenance treatment for atypical hemolytic uremic syndrome: a report of 10 cases","volume":"64","author":"Ardissino","year":"2014","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.trre.2024.100857_bb0360","doi-asserted-by":"crossref","first-page":"1939","DOI":"10.1093\/ckj\/sfaa241","article-title":"Outcome of atypical haemolytic uraemic syndrome relapse after eculizumab withdrawal","volume":"14","author":"Duineveld","year":"2020","journal-title":"Clin Kidney J"},{"key":"10.1016\/j.trre.2024.100857_bb0365","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12882-019-1314-1","article-title":"Outcomes in patients with atypical hemolytic uremic syndrome treated with eculizumab in a long-term observational study","volume":"20","author":"Menne","year":"2019","journal-title":"BMC Nephrol"},{"key":"10.1016\/j.trre.2024.100857_bb0370","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1016\/j.kint.2020.01.035","article-title":"The long-acting C5 inhibitor, ravulizumab, is effective and safe in adult patients with atypical hemolytic uremic syndrome na\u00efve to complement inhibitor treatment","volume":"97","author":"Rondeau","year":"2020","journal-title":"Kidney Int"},{"key":"10.1016\/j.trre.2024.100857_bb0375","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.kint.2020.10.046","article-title":"The long-acting C5 inhibitor, ravulizumab, is effective and safe in pediatric patients with atypical hemolytic uremic syndrome na\u00efve to complement inhibitor treatment","volume":"100","author":"Ariceta","year":"2021","journal-title":"Kidney Int"},{"key":"10.1016\/j.trre.2024.100857_bb0380","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1007\/s00467-012-2131-y","article-title":"Atypical hemolytic uremic syndrome in children: complement mutations and clinical characteristics","volume":"27","author":"Geerdink","year":"2012","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.trre.2024.100857_bb0385","doi-asserted-by":"crossref","first-page":"2180","DOI":"10.1681\/ASN.2010030315","article-title":"Clinical features of anti-factor H autoantibody\u2013associated hemolytic uremic syndrome","volume":"21","author":"Dragon-Durey","year":"2010","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.trre.2024.100857_bb0390","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1007\/s00467-008-0964-1","article-title":"Guideline for the investigation and initial therapy of diarrhea-negative hemolytic uremic syndrome","volume":"24","author":"Ariceta","year":"2009","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.trre.2024.100857_bb0395","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1111\/j.1399-3046.2008.00910.x","article-title":"Hemolytic uremic syndrome recurrence after renal transplantation","volume":"12","author":"Loirat","year":"2008","journal-title":"Pediatr Transplant"},{"key":"10.1016\/j.trre.2024.100857_bb0400","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.1056\/NEJMc1001060","article-title":"Prophylactic eculizumab after renal transplantation in atypical hemolytic\u2013uremic syndrome","volume":"362","author":"Zimmerhackl","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.trre.2024.100857_bb0405","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1056\/NEJMc0808527","article-title":"Eculizumab for atypical hemolytic\u2013uremic syndrome","volume":"360","author":"N\u00fcrnberger","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.trre.2024.100857_bb0410","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1007\/s00467-010-1708-6","article-title":"Eculizumab induces long-term remission in recurrent post-transplant HUS associated with C3 gene mutation","volume":"26","author":"Al-Akash","year":"2011","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.trre.2024.100857_bb0415","doi-asserted-by":"crossref","first-page":"4353","DOI":"10.1016\/j.transproceed.2010.09.125","article-title":"Hurault de Ligny B. Eculizumab: safety and efficacy after 17 months of treatment in a renal transplant patient with recurrent atypical hemolytic-uremic syndrome: case report","volume":"42","author":"Ch\u00e2telet","year":"2010","journal-title":"Transplant Proc"},{"key":"10.1016\/j.trre.2024.100857_bb0420","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1097\/TP.0b013e3181ccd80d","article-title":"Efficacy of Eculizumab in the treatment of recurrent atypical hemolytic-uremic syndrome after renal transplantation","volume":"89","author":"Larrea","year":"2010","journal-title":"Transplantation"},{"key":"10.1016\/j.trre.2024.100857_bb0425","doi-asserted-by":"crossref","first-page":"2449","DOI":"10.1681\/ASN.2019040331","article-title":"Use of highly individualized complement blockade has revolutionized clinical outcomes after kidney transplantation and renal epidemiology of atypical hemolytic uremic syndrome","volume":"30","author":"Zuber","year":"2019","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.trre.2024.100857_bb0430","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1186\/s12882-020-01847-0","article-title":"Ten-year outcome of Eculizumab in kidney transplant recipients with atypical hemolytic uremic syndrome \u2013 a single center experience","volume":"21","author":"Kant","year":"2020","journal-title":"BMC Nephrol"},{"key":"10.1016\/j.trre.2024.100857_bb0435","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0258319","article-title":"Thrombotic microangiopathy after kidney transplantation: analysis of the Brazilian atypical hemolytic uremic syndrome cohort","volume":"16","author":"Nga","year":"2021","journal-title":"PloS One"},{"key":"10.1016\/j.trre.2024.100857_bb0440","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1093\/ckj\/sfaa096","article-title":"Characteristics, management and outcomes of atypical haemolytic uraemic syndrome in kidney transplant patients: a retrospective national study","volume":"14","author":"Portoles","year":"2020","journal-title":"Clin Kidney J"},{"key":"10.1016\/j.trre.2024.100857_bb0445","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1097\/TP.0000000000004355","article-title":"Assessing the impact of prophylactic eculizumab on renal graft survival in atypical hemolytic uremic syndrome","volume":"107","author":"Glover","year":"2023","journal-title":"Transplantation"},{"key":"10.1016\/j.trre.2024.100857_bb0450","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1053\/j.ajkd.2017.06.024","article-title":"Living donor kidney transplantation in atypical hemolytic uremic syndrome: a case series","volume":"70","author":"Duineveld","year":"2017","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.trre.2024.100857_bb0455","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/j.ekir.2018.11.010","article-title":"Eculizumab use for kidney transplantation in patients with a diagnosis of atypical hemolytic uremic syndrome","volume":"4","author":"Siedlecki","year":"2018","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.trre.2024.100857_bb0460","doi-asserted-by":"crossref","first-page":"919","DOI":"10.3390\/jcm8070919","article-title":"Outcomes of kidney transplant patients with atypical hemolytic uremic syndrome treated with eculizumab: a systematic review and meta-analysis","volume":"8","author":"Gonzalez Suarez","year":"2019","journal-title":"J Clin Med"},{"key":"10.1016\/j.trre.2024.100857_bb0465","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1097\/TP.0000000000000200","article-title":"Atypical hemolytic uremic syndrome recurrence after kidney transplantation","volume":"98","author":"Matar","year":"2014","journal-title":"Transplantation"},{"key":"10.1016\/j.trre.2024.100857_bb0470","first-page":"310","article-title":"Current evidence on the discontinuation of eculizumab in patients with atypical haemolytic uraemic syndrome","volume":"10","author":"Macia","year":"2017","journal-title":"Clin Kidney J"},{"key":"10.1016\/j.trre.2024.100857_bb0475","doi-asserted-by":"crossref","first-page":"714","DOI":"10.12659\/AOT.894665","article-title":"Prophylactic eculizumab use in kidney transplantation: a review of the literature and report of a case with atypical hemolytic uremic syndrome","volume":"20","author":"Kasapo\u011flu","year":"2015","journal-title":"Ann Transplant"},{"key":"10.1016\/j.trre.2024.100857_bb0480","doi-asserted-by":"crossref","first-page":"2924","DOI":"10.1097\/TP.0000000000001909","article-title":"Midterm outcomes of 12 renal transplant recipients treated with eculizumab to prevent atypical hemolytic syndrome recurrence","volume":"101","author":"Levi","year":"2017","journal-title":"Transplantation"},{"key":"10.1016\/j.trre.2024.100857_bb0485","author":"Novartis Pharmaceuticals"},{"key":"10.1016\/j.trre.2024.100857_bb0490","author":"Roche"}],"container-title":["Transplantation Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0955470X24000405?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0955470X24000405?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,5,14]],"date-time":"2024-05-14T20:29:46Z","timestamp":1715718586000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0955470X24000405"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7]]},"references-count":98,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["S0955470X24000405"],"URL":"https:\/\/doi.org\/10.1016\/j.trre.2024.100857","relation":{},"ISSN":["0955-470X"],"issn-type":[{"value":"0955-470X","type":"print"}],"subject":[],"published":{"date-parts":[[2024,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Recurrent complement-mediated Hemolytic uremic syndrome after kidney transplantation","name":"articletitle","label":"Article Title"},{"value":"Transplantation Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.trre.2024.100857","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"100857"}}